奥西默替尼
T790米
医学
表皮生长因子受体
肺癌
腺癌
突变
癌症研究
表皮生长因子
肿瘤科
内科学
癌症
受体
基因
遗传学
生物
埃罗替尼
吉非替尼
作者
Noriaki Ito,Takeshi Masuda,Ikuko Ooka,Takatsune Hosoya,Kakuhiro Yamaguchi,Shinjiro Sakamoto,Yasushi Horimasu,Taku Nakashima,Shintaro Miyamoto,Hiroshi Iwamoto,Kazunori Fujitaka,Hironobu Hamada,Noboru Hattori
标识
DOI:10.1111/1759-7714.14288
摘要
Osimertinib is the standard treatment for non-small cell lung cancer (NSCLC) with an active epidermal growth factor receptor (EGFR) mutation and a T790M mutation-present in cases of acquired resistance. However, there have been no reports on the efficacy of osimertinib in patients with EGFR G719S and de novo T790M mutations. Here, we present the case of a 71-year-old woman who received first-line osimertinib for lung adenocarcinoma with G719S and de novo T790M mutations. A partial response was observed after osimertinib initiation; however, the disease progressed 5 months after. Next-generation sequencing using a rebiopsy sample from the brain metastases revealed no newly acquired resistance mutations, including EGFR C797S. From experience, the efficacy of osimertinib in NSCLC with G719S and T790M compound mutations may be poor. Therefore, optimal treatment for these cases should be determined.
科研通智能强力驱动
Strongly Powered by AbleSci AI